Systemic Lupus Erythematosus

  • Stefanie DeedsEmail author


Systemic lupus erythematosus (SLE) is a multisystem inflammatory disease associated with increased risk of cardiovascular, renal, and thrombotic complications. Patients with SLE are at increased risk for perioperative complications and mortality. The evaluation of patients with SLE undergoing surgery should include special attention to the presence of risk factors for surgical complications and management of often complex medication regimens.


Systemic lupus erythematosus Perioperative Cardiovascular disease Thromboembolic disease Arthroplasty 



Gregory Gardner, M.D., F.A.C.P., Professor, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA.


  1. 1.
    Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48(6):673–5.CrossRefGoogle Scholar
  2. 2.
    Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33:1570–7.PubMedGoogle Scholar
  3. 3.
    Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018;355(3):293–8.CrossRefGoogle Scholar
  4. 4.
    Zuily S, Regnault V, Selton-Suty C, Eschwège V, Bruntz JF, Bode-Dotto E, De Maistre E, Dotto P, Perret-Guillaume C, Lecompte T, Wahl D. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215–24.CrossRefGoogle Scholar
  5. 5.
    Zuily S, Domingues V, Suty-Selton C, Eschwège V, Bertoletti L, Chaouat A, Chabot F, Regnault V, Horn EM, Erkan D, Wahl D. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: a systematic review and meta-analysis. Autoimmun Rev. 2017;16(6):576–86.CrossRefGoogle Scholar
  6. 6.
    Kasturi S, Goodman S. Current perspectives on arthroplasty in systemic lupus erythematosus: rates, outcomes, and adverse events. Curr Rheumatol Rep. 2016;18(9):59. Open image in new windowGoogle Scholar
  7. 7.
    Smilowitz NR, Katz G, Buyon JP, Clancy RM, Berger JS. Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. J Thromb Thrombolysis. 2018;45(1):13–7.CrossRefGoogle Scholar
  8. 8.
    Babazade R, Yilmaz HO, Leung SM, Zimmerman NM, Turan A. Systemic lupus erythematosus is associated with increased adverse postoperative renal outcomes and mortality: a historical cohort study using administrative health data. Anesth Analg. 2017;124(4):1118–26.CrossRefGoogle Scholar
  9. 9.
    Lin JA, Liao CC, Lee YJ, Wu CH, Huang WQ, Chen TL. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73(9):1646–51.CrossRefGoogle Scholar
  10. 10.
    Roberts JE, Mandl LA, Su EP, Mayman DJ, Figgie MP, Fein AW, Lee YY, Shah U, Goodman SM. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43(8):1498–502.CrossRefGoogle Scholar
  11. 11.
    Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29(4):843–9.PubMedGoogle Scholar
  12. 12.
    Gualtierotti R, Parisi M, Ingegnoli F. Perioperative management of patients with inflammatory rheumatic diseases undergoing major orthopaedic surgery: a practical overview. Adv Ther. 2018;35(4):439–56. Open image in new windowGoogle Scholar
  13. 13.
    Wu H, Birmingham DJ, Rovin B, et al. D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol. 2008;3(6):1628–36. Scholar
  14. 14.
    Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95.CrossRefGoogle Scholar
  15. 15.
    Yazdanyar A, Wasko MC, Scalzi LV, Kraemer KL, Ward MM. Short-term perioperative all-cause mortality and cardiovascular events in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(6):986–91.CrossRefGoogle Scholar
  16. 16.
    Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69(8):1111–24. Open image in new windowGoogle Scholar
  17. 17.
    Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.CrossRefGoogle Scholar
  18. 18.
    Goodman SM, Bass AR. Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review. BMC Rheumatol. 2018;2(2):2.CrossRefGoogle Scholar
  19. 19.
    Petri M, Kim M, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. NEJM. 2005;353(24):2550–8.CrossRefGoogle Scholar
  20. 20.
    Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of General Internal MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations